XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2
Basis of presentation (Tables)
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet
The tables below present the impact of the revision on the line items within the Company’s consolidated financial statements for the relevant periods:
 
 
  
Three months ended
 
  
Six months ended
 
 
  
June 30, 2023
 
  
June 30, 2023
 
 
  
U.S. $ in millions (except per share amounts)
 
 
  
(Unaudited)
 
 
  
As
previously
reported
 
  
Adjustment
 
  
As revised
 
  
As
previously
reported
 
  
Adjustment
 
  
As revised
 
Other asset impairments, restructuring and other items
   $ 100       8       108     $ 195       23       218  
Operating income (loss)
     (646)       (8)       (654)       (644)       (23)       (667)  
Income (loss) before income taxes
     (914)       (8)       (923)       (1,172)       (23)       (1,195)  
Income taxes (benefit)
     (16)       §       (16)       (35)       —        (35)  
Net income (loss)
     (898)       (8)       (906)       (1,136)       (23)       (1,159)  
Net income (loss) attributable to Teva
     (863)       (8)       (872)       (1,068)       (23)       (1,091)
Basic and diluted loss per share
   $ (0.77)       (0.01)       (0.78)     $ (0.96)       (0.02)       (0.98)  
§ 
Represents an amount less than $0.5 million.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     June 30, 2023  
     As
previously
reported
     Adjustment      As revised  
     U.S. $ in millions  
     (Unaudited)  
Deferred income taxes
   $ 1,578        5        1,583  
Total assets
     43,095        5        43,100  
Other taxes and long-term liabilities
     3,973        121        4,094  
Total long-term liabilities
     23,543        121        23,664  
Total liabilities
     35,387        121        35,508  
Teva shareholders’ equity:
        
Accumulated deficit
     (13,950      (116      (14,066
Total equity
     7,708        (116      7,592  
Total liabilities and equity
   $ 43,095        5        43,100